Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financial Analysts Roundtable: Medicare Part D, Big Pharma Diversification And The Outlook For M&A

Executive Summary

Three large cap pharmaceutical analysts sat down with "The Pink Sheet" in January to discuss the outlook for the drug industry in 2007. Below are excerpts from a conversation with Prudential's Tim Anderson, Goldman Sachs' Jim Kelly and Morgan Stanley's Jami Rubin. 1Kelly and 2Rubin provided "The Pink Sheet" with extensive disclosure statements, which can be accessed by visiting 3www.ThePinkSheet.com. In the second part of the series, slated to appear in the Feb. 12 issue, the analysts discuss the impact of the changes on Capitol Hill and the regulatory climate.

You may also be interested in...



Year In Review: Is Big Pharma Getting Smaller? Cost-Cutting Fails To Revive Rx Stocks

As the pharmaceutical industry wades through its second spate of major restructuring initiatives in the last three years, investors may be weighing whether the programs reflect efforts to improve efficiency in the face of short-term setbacks, or suggest a more fundamental long-term downsizing of the brand industry

Year In Review: Is Big Pharma Getting Smaller? Cost-Cutting Fails To Revive Rx Stocks

As the pharmaceutical industry wades through its second spate of major restructuring initiatives in the last three years, investors may be weighing whether the programs reflect efforts to improve efficiency in the face of short-term setbacks, or suggest a more fundamental long-term downsizing of the brand industry

Schering Jumps On Organon Buy; Will Late-Stage M&A Keep Fueling Pharma?

Pharmaceutical companies unveiling mergers and acquisitions in the first quarter were among those rewarded by Wall Street

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS047996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel